Rapport Therapeutics, Inc. RAPP
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -55.31% | -34.60% | -42.37% | -35.99% | -- |
| Total Depreciation and Amortization | -1.54% | 7.41% | 21.22% | 60.13% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 85.50% | 107.14% | 29.46% | 48.39% | -- |
| Change in Net Operating Assets | 554.13% | 929.22% | 244.95% | 168.17% | -- |
| Cash from Operations | -26.93% | -19.05% | -34.93% | -27.13% | -- |
| Capital Expenditure | 31.22% | 74.69% | 74.39% | 81.39% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -821.21% | -61.19% | -11.40% | 107.02% | -- |
| Cash from Investing | -844.18% | -59.13% | -10.19% | 106.69% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,101,300.00% | 70.69% | 70.19% | 70.01% | -- |
| Repurchase of Common Stock | 99.64% | 99.64% | 99.93% | 99.93% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -520.63% | -196.47% | -- | 100.00% | -- |
| Cash from Financing | 18,977.92% | 71.75% | 22.18% | 22.13% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 115.51% | 222.74% | 68.82% | 276.71% | -- |